Cargando…

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

BACKGROUND: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic action. We recently reported that the SGLT2 inhibitor dapagliflozin ameliorates extracellular volume expansion with a mild increase in urine volume. However, the impact of the pretreatment extra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohara, Ken, Masuda, Takahiro, Morinari, Masato, Okada, Mari, Miki, Atsushi, Nakagawa, Saki, Murakami, Takuya, Oka, Kentaro, Asakura, Maki, Miyazawa, Yasuharu, Maeshima, Akito, Akimoto, Tetsu, Saito, Osamu, Nagata, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195732/ https://www.ncbi.nlm.nih.gov/pubmed/32377235 http://dx.doi.org/10.1186/s13098-020-00545-z

Ejemplares similares

Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease
por: Nagayama, Izumi, et al.
Publicado: (2019)

Kartagener syndrome complicated by immunoglobulin A nephropathy
por: Oka, Kentaro, et al.
Publicado: (2018)

Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis and Malignancy: A Case of a Patient Diagnosed with Renal Failure and Pulmonary Carcinoma Concurrently
por: Asakura, Maki, et al.
Publicado: (2021)

Hemolytic Uremic Syndrome: An Increasingly Recognized Public Health Problem
por: Murakami, Takuya, et al.
Publicado: (2018)

Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention
por: Imai, Toshimi, et al.
Publicado: (2015)

Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention
por: Masuda, Takahiro, et al.
Publicado: (2016)

Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death
por: Shibusawa, Ryo, et al.
Publicado: (2019)

Antineutrophil Cytoplasmic Antibody–associated Glomerulonephritis Complicated by Pneumatosis Intestinalis
por: Nakagawa, Saki, et al.
Publicado: (2015)

Nephrotic Syndrome and a Retroperitoneal Mass: A Case Report of a Patient with Recurrent Invasive Thymoma
por: Myoga, Hiroaki, et al.
Publicado: (2017)

Minimal Change Nephrotic Syndrome Sequentially Complicated by Acute Kidney Injury and Painful Skin Ulcers due to Calciphylaxis
por: Sato, Ryuta, et al.
Publicado: (2016)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Valacyclovir Neurotoxicity and Nephrotoxicity in an Elderly Patient Complicated by Hyponatremia
por: Murakami, Takuya, et al.
Publicado: (2018)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

Peritoneal Dialysis and Retroperitoneal Laparoscopic Radical Nephrectomy: A Favorable Experience With a Patient Complicated by Renal Cell Carcinoma
por: Imai, Reika, et al.
Publicado: (2017)

Therapeutic Challenges to End-Stage Kidney Disease in a Patient with Tetralogy of Fallot
por: Ohara, Ken, et al.
Publicado: (2015)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
por: Hodrea, Judit, et al.
Publicado: (2022)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
por: Dobner, Stephan, et al.
Publicado: (2022)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Retroperitoneal Bleeding: An Experience During Prophylactic Anticoagulation in a Patient With Nephrotic Syndrome
por: Okada, Mari, et al.
Publicado: (2017)

Pleuroperitoneal Communication and Ovarian Cancer Complicating Peritoneal Dialysis: A Case Report of a Patient with End-Stage Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2017)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(−/−) Mice
por: Leng, Weiling, et al.
Publicado: (2016)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen, Thiquynhnga, et al.
Publicado: (2020)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2022)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
por: op den Kamp, Yvo J.M., et al.
Publicado: (2022)

Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
por: Kohara, Marina, et al.
Publicado: (2017)

Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
por: Masuda, Takahiro, et al.
Publicado: (2020)

Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
por: Erdogan, Mumin Alper, et al.
Publicado: (2018)

The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis
por: Wallenius, Kristina, et al.
Publicado: (2022)

Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms
por: Eldesoqui, Mamdouh, et al.
Publicado: (2022)

Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
por: Fu, Qianyu, et al.
Publicado: (2023)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Yavin, Yshai, et al.
Publicado: (2016)

Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus
por: Chen, Ying-Ying, et al.
Publicado: (2019)

Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney
por: Hodrea, Judit, et al.
Publicado: (2020)

Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials
por: Huang, Yuxin, et al.
Publicado: (2021)

The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb
por: Resaz, Roberta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_neviaqogcfsj88ms4qc82gmcvd